For starters, it’s important to note that these successes come in one of the easier parts of drug development (not that any part of it can really be said to be easy). The AIs weren’t being asked to design entirely new molecules, and most drugs fail during the animal and clinical trials phase, rather than during testing in cell culture. That’s not to say repurposing existing drugs is nothing—we already have safety profiles and agency approvals for these molecules, and many are off-patent and therefore cheap. But we’re not at the point where AIs are solving hard problems. This sort of hypothesis
Two AI-based science assistants succeed with drug-retargeting tasks… Barnacle, Jr., assistant director in charge of the New York FBI field office, confirmed that his agents would continue investigating similar cases. “This predatory conduct represents a disturbing abuse of technology that inflicts emotional harm on victims, violating their privacy, dignity, and secu… …
… Now, Anthropic says it thinks this “misalignment” was primarily the result of training on “internet text that portrays AI as evil and interested in self-preservation.” In a recent technical post on Anthropic’s Alignment Science blog and an accompanying social media thread and public-facing blog pos… …
… That’s not to say repurposing existing drugs is nothing—we already have safety profiles and agency approvals for these molecules, and many are off-patent and therefore cheap. But we’re not at the point where AIs are solving hard problems. …
… At least one researcher said Thursday that a cursory look at the reports showed they were “ pretty impressive .” Unlike previous vulnerability disclosure slop, Grinstead said, the details provided by its harness-guided Mythos analysis, and confirmed by the second LLM, and ultimately included in the… …